{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:36:54Z","timestamp":1794850614825,"version":"4.9.1"},"reference-count":339,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41569-020-0339-2","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T09:03:35Z","timestamp":1582189415000},"page":"585-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":778,"title":["Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9798-6237","authenticated-orcid":false,"given":"Yi","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-6423","authenticated-orcid":false,"given":"Zhiguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kupper A.","family":"Wintergerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-6050","authenticated-orcid":false,"given":"Bradley B.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-1135","authenticated-orcid":false,"given":"Lu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"339_CR1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler, S. et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595\u2013602 (1972).","journal-title":"Am. J. Cardiol."},{"key":"339_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel, W. B., Hjortland, M. & Castelli, W. P. Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29\u201334 (1974).","journal-title":"Am. J. Cardiol."},{"key":"339_CR3","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.2174\/0929867324666170705111356","volume":"25","author":"R Tarquini","year":"2018","unstructured":"Tarquini, R. et al. Clinical approach to diabetic cardiomyopathy: a review of human studies. Curr. Med. Chem. 25, 1510\u20131524 (2018).","journal-title":"Curr. Med. Chem."},{"key":"339_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1479164118787415","volume":"15","author":"S Bouthoorn","year":"2018","unstructured":"Bouthoorn, S. et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diab. Vasc. Dis. Res. 15, 477\u2013493 (2018).","journal-title":"Diab. Vasc. Dis. Res."},{"key":"339_CR5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2337\/dc17-0697","volume":"40","author":"M Dauriz","year":"2017","unstructured":"Dauriz, M. et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40, 1597\u20131605 (2017).","journal-title":"Diabetes Care"},{"key":"339_CR6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005156","volume":"6","author":"M Dauriz","year":"2017","unstructured":"Dauriz, M. et al. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. J. Am. Heart Assoc. 6, e005156 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"339_CR7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00592-013-0455-0","volume":"50","author":"E Konduracka","year":"2013","unstructured":"Konduracka, E. et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 50, 597\u2013606 (2013).","journal-title":"Acta Diabetol."},{"key":"339_CR8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia, G., Hill, M. A. & Sowers, J. R. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 122, 624\u2013638 (2018).","journal-title":"Circ. Res."},{"key":"339_CR9","doi-asserted-by":"crossref","unstructured":"[No authors listed] Professional Practice Committee: Standards of Medical Care in Diabetes\u20132018. Diabetes Care 41, S3 (2018).","DOI":"10.2337\/dc18-Sppc01"},{"key":"339_CR10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","volume":"319","author":"SL Zheng","year":"2018","unstructured":"Zheng, S. L. et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319, 1580\u20131591 (2018).","journal-title":"JAMA"},{"key":"339_CR11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica, B. M. et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130, 1579\u20131588 (2014).","journal-title":"Circulation"},{"key":"339_CR12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","volume":"139","author":"DK McGuire","year":"2019","unstructured":"McGuire, D. K. et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 139, 351\u2013361 (2019).","journal-title":"Circulation"},{"key":"339_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357 (2019).","journal-title":"N. Engl. J. Med."},{"key":"339_CR14","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato, E. T. et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139, 2528\u20132536 (2019).","journal-title":"Circulation"},{"key":"339_CR15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado, R. H. M. et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139, 2516\u20132527 (2019).","journal-title":"Circulation"},{"key":"339_CR16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel, M. A. et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 6, 105\u2013113 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"339_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(18)30320-6","volume":"7","author":"H Svanstrom","year":"2019","unstructured":"Svanstrom, H. et al. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 7, 106\u2013114 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"339_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","volume":"18","author":"MB Bizino","year":"2019","unstructured":"Bizino, M. B. et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc. Diabetol. 18, 55 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"339_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00395-018-0711-0","volume":"114","author":"C Riehle","year":"2018","unstructured":"Riehle, C. & Bauersachs, J. Of mice and men: models and mechanisms of diabetic cardiomyopathy. Basic Res. Cardiol. 114, 2 (2018).","journal-title":"Basic Res. Cardiol."},{"key":"339_CR21","doi-asserted-by":"crossref","first-page":"E2136","DOI":"10.3390\/ijms17122136","volume":"17","author":"ME Holscher","year":"2016","unstructured":"Holscher, M. E., Bode, C. & Bugger, H. Diabetic cardiomyopathy: does the type of diabetes matter? Int. J. Mol. Sci. 17, E2136 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"339_CR22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"G Jia","year":"2016","unstructured":"Jia, G., DeMarco, V. G. & Sowers, J. R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat. Rev. Endocrinol. 12, 144\u2013153 (2016).","journal-title":"Nat. Rev. Endocrinol."},{"key":"339_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia, G., Whaley-Connell, A. & Sowers, J. R. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 61, 21\u201328 (2018).","journal-title":"Diabetologia"},{"key":"339_CR24","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00125-015-3691-8","volume":"58","author":"A Bonen","year":"2015","unstructured":"Bonen, A. et al. Extremely rapid increase in fatty acid transport and intramyocellular lipid accumulation but markedly delayed insulin resistance after high fat feeding in rats. Diabetologia 58, 2381\u20132391 (2015).","journal-title":"Diabetologia"},{"key":"339_CR25","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1210\/en.2005-0938","volume":"146","author":"J Buchanan","year":"2005","unstructured":"Buchanan, J. et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146, 5341\u20135349 (2005).","journal-title":"Endocrinology"},{"key":"339_CR26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.bbamcr.2011.01.014","volume":"1813","author":"JG Duncan","year":"2011","unstructured":"Duncan, J. G. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim. Biophys. Acta 1813, 1351\u20131359 (2011).","journal-title":"Biochim. Biophys. Acta"},{"key":"339_CR27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ncpcardio1347","volume":"5","author":"D Lebeche","year":"2008","unstructured":"Lebeche, D., Davidoff, A. J. & Hajjar, R. J. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med. 5, 715\u2013724 (2008).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"339_CR28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fnins.2018.00591","volume":"12","author":"AI Vinik","year":"2018","unstructured":"Vinik, A. I., Casellini, C., Parson, H. K., Colberg, S. R. & Nevoret, M. L. Cardiac autonomic neuropathy in diabetes: a predictor of cardiometabolic events. Front. Neurosci. 12, 591 (2018).","journal-title":"Front. Neurosci."},{"key":"339_CR29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2018.12.064","volume":"73","author":"JJ Goldberger","year":"2019","unstructured":"Goldberger, J. J., Arora, R., Buckley, U. & Shivkumar, K. Autonomic nervous system dysfunction: JACC focus seminar. J. Am. Coll. Cardiol. 73, 1189\u20131206 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR30","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"PM Seferovic","year":"2015","unstructured":"Seferovic, P. M. & Paulus, W. J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur. Heart J. 36, 1718\u20131727 (2015).","journal-title":"Eur. Heart J."},{"key":"339_CR31","doi-asserted-by":"crossref","first-page":"H125","DOI":"10.1152\/ajpheart.00165.2009","volume":"297","author":"T Radovits","year":"2009","unstructured":"Radovits, T. et al. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 297, H125\u2013H133 (2009).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"339_CR32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","volume":"134","author":"SJ Shah","year":"2016","unstructured":"Shah, S. J. et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 134, 73\u201390 (2016).","journal-title":"Circulation"},{"key":"339_CR33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","volume":"117","author":"L van Heerebeek","year":"2008","unstructured":"van Heerebeek, L. et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43\u201351 (2008).","journal-title":"Circulation"},{"key":"339_CR34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/db15-0568","volume":"65","author":"B Vulesevic","year":"2016","unstructured":"Vulesevic, B. et al. Methylglyoxal-induced endothelial cell loss and inflammation contribute to the development of diabetic cardiomyopathy. Diabetes 65, 1699\u20131713 (2016).","journal-title":"Diabetes"},{"key":"339_CR35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/cvr\/cvw159","volume":"111","author":"A Wan","year":"2016","unstructured":"Wan, A. & Rodrigues, B. Endothelial cell-cardiomyocyte crosstalk in diabetic cardiomyopathy. Cardiovasc. Res. 111, 172\u2013183 (2016).","journal-title":"Cardiovasc. Res."},{"key":"339_CR36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12872-016-0288-1","volume":"16","author":"L Brunvand","year":"2016","unstructured":"Brunvand, L., Fugelseth, D., Stensaeth, K. H., Dahl-Jorgensen, K. & Margeirsdottir, H. D. Early reduced myocardial diastolic function in children and adolescents with type 1 diabetes mellitus a population-based study. BMC Cardiovasc. Disord. 16, 103 (2016).","journal-title":"BMC Cardiovasc. Disord."},{"key":"339_CR37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12872-017-0551-0","volume":"17","author":"L Brunvand","year":"2017","unstructured":"Brunvand, L. et al. Advanced glycation end products in children with type 1 diabetes and early reduced diastolic heart function. BMC Cardiovasc. Disord. 17, 133 (2017).","journal-title":"BMC Cardiovasc. Disord."},{"key":"339_CR38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2337\/diacare.17.7.633","volume":"17","author":"DC Raev","year":"1994","unstructured":"Raev, D. C. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 17, 633\u2013639 (1994).","journal-title":"Diabetes Care"},{"key":"339_CR39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ahj.2004.06.021","volume":"149","author":"ZY Fang","year":"2005","unstructured":"Fang, Z. Y. et al. Screening for heart disease in diabetic subjects. Am. Heart J. 149, 349\u2013354 (2005).","journal-title":"Am. Heart J."},{"key":"339_CR40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-014-0168-x","volume":"14","author":"R Fontes-Carvalho","year":"2015","unstructured":"Fontes-Carvalho, R., Ladeiras-Lopes, R., Bettencourt, P., Leite-Moreira, A. & Azevedo, A. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc. Diabetol. 14, 4 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12872-016-0242-2","volume":"16","author":"D Suran","year":"2016","unstructured":"Suran, D., Sinkovic, A. & Naji, F. Tissue Doppler imaging is a sensitive echocardiographic technique to detect subclinical systolic and diastolic dysfunction of both ventricles in type 1 diabetes mellitus. BMC Cardiovasc. Disord. 16, 72 (2016).","journal-title":"BMC Cardiovasc. Disord."},{"key":"339_CR42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-017-0645-0","volume":"17","author":"C Matyas","year":"2018","unstructured":"Matyas, C. et al. Comparison of speckle-tracking echocardiography with invasive hemodynamics for the detection of characteristic cardiac dysfunction in type-1 and type-2 diabetic rat models. Cardiovasc. Diabetol. 17, 13 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick, T. H., Ritchie, R., Shaw, J. E. & Kaye, D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 71, 339\u2013351 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10741-018-9749-1","volume":"24","author":"B Parim","year":"2019","unstructured":"Parim, B., Sathibabu Uddandrao, V. V. & Saravanan, G. Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy. Heart Fail. Rev. 24, 279\u2013299 (2019).","journal-title":"Heart Fail. Rev."},{"key":"339_CR45","first-page":"59","volume":"4","author":"S Nunes","year":"2012","unstructured":"Nunes, S., Soares, E., Pereira, F. & Reis, F. The role of inflammation in diabetic cardiomyopathy. Int. J. Infereron Cytokine Mediator Res. 4, 59\u201373 (2012).","journal-title":"Int. J. Infereron Cytokine Mediator Res."},{"key":"339_CR46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny, H. C. & Abel, E. D. Heart failure in type 2 diabetes mellitus. Circ. Res. 124, 121\u2013141 (2019).","journal-title":"Circ. Res."},{"key":"339_CR47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/CIRCRESAHA.117.312166","volume":"123","author":"AE Hopf","year":"2018","unstructured":"Hopf, A. E. et al. Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by neuregulin-1. Circ. Res. 123, 342\u2013355 (2018).","journal-title":"Circ. Res."},{"key":"339_CR48","doi-asserted-by":"crossref","first-page":"2974304","DOI":"10.1155\/2018\/2974304","volume":"2018","author":"L Al Kury","year":"2018","unstructured":"Al Kury, L. et al. Calcium signaling in the ventricular myocardium of the Goto-Kakizaki type 2 diabetic rat. J. Diabetes Res. 2018, 2974304 (2018).","journal-title":"J. Diabetes Res."},{"key":"339_CR49","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","volume":"39","author":"C Maack","year":"2018","unstructured":"Maack, C. et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur. Heart J. 39, 4243\u20134254 (2018).","journal-title":"Eur. Heart J."},{"key":"339_CR50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.bbadis.2013.09.004","volume":"1832","author":"PK Mishra","year":"2013","unstructured":"Mishra, P. K., Givvimani, S., Chavali, V. & Tyagi, S. C. Cardiac matrix: a clue for future therapy. Biochim. Biophys. Acta 1832, 2271\u20132276 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"339_CR51","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/cphy.c140063","volume":"5","author":"MA Horn","year":"2015","unstructured":"Horn, M. A. Cardiac physiology of aging: extracellular considerations. Compr. Physiol. 5, 1069\u20131121 (2015).","journal-title":"Compr. Physiol."},{"key":"339_CR52","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1161\/01.CIR.93.10.1905","volume":"93","author":"GR Norton","year":"1996","unstructured":"Norton, G. R., Candy, G. & Woodiwiss, A. J. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93, 1905\u20131912 (1996).","journal-title":"Circulation"},{"key":"339_CR53","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/diacare.22.7.1186","volume":"22","author":"TJ Berg","year":"1999","unstructured":"Berg, T. J. et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22, 1186\u20131190 (1999).","journal-title":"Diabetes Care"},{"key":"339_CR54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3346\/jkms.2009.24.1.32","volume":"24","author":"SY Choi","year":"2009","unstructured":"Choi, S. Y. et al. Long-term exercise training attenuates age-related diastolic dysfunction: association of myocardial collagen cross-linking. J. Korean Med. Sci. 24, 32\u201339 (2009).","journal-title":"J. Korean Med. Sci."},{"key":"339_CR55","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/CIRCRESAHA.109.209809","volume":"105","author":"CA Souders","year":"2009","unstructured":"Souders, C. A., Bowers, S. L. & Baudino, T. A. Cardiac fibroblast: the renaissance cell. Circ. Res. 105, 1164\u20131176 (2009).","journal-title":"Circ. Res."},{"key":"339_CR56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00395-008-0715-2","volume":"103","author":"S Van Linthout","year":"2008","unstructured":"Van Linthout, S. et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 103, 319\u2013327 (2008).","journal-title":"Basic Res. Cardiol."},{"key":"339_CR57","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","volume":"118","author":"JG Travers","year":"2016","unstructured":"Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E. & Blaxall, B. C. Cardiac fibrosis: the fibroblast awakens. Circ. Res. 118, 1021\u20131040 (2016).","journal-title":"Circ. Res."},{"key":"339_CR58","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm1613","volume":"13","author":"EM Zeisberg","year":"2007","unstructured":"Zeisberg, E. M. et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952\u2013961 (2007).","journal-title":"Nat. Med."},{"key":"339_CR59","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1161\/CIRCRESAHA.110.235531","volume":"108","author":"CL Smith","year":"2011","unstructured":"Smith, C. L., Baek, S. T., Sung, C. Y. & Tallquist, M. D. Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ. Res. 108, e15\u2013e26 (2011).","journal-title":"Circ. Res."},{"key":"339_CR60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","volume":"4","author":"C Franssen","year":"2016","unstructured":"Franssen, C. et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 4, 312\u2013324 (2016).","journal-title":"JACC Heart Fail."},{"key":"339_CR61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacbts.2017.05.004","volume":"2","author":"L Cruz","year":"2017","unstructured":"Cruz, L. & Ryan, J. J. Nitric oxide signaling in heart failure with preserved ejection fraction. JACC Basic. Transl Sci. 2, 341\u2013343 (2017).","journal-title":"JACC Basic. Transl Sci."},{"key":"339_CR62","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ejhf.711","volume":"19","author":"C Matyas","year":"2017","unstructured":"Matyas, C. et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur. J. Heart Fail. 19, 326\u2013336 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR63","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/cvr\/cvy038","volume":"114","author":"O Sorop","year":"2018","unstructured":"Sorop, O. et al. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovasc. Res. 114, 954\u2013964 (2018).","journal-title":"Cardiovasc. Res."},{"key":"339_CR64","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","volume":"35","author":"TC Wong","year":"2014","unstructured":"Wong, T. C. et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur. Heart J. 35, 657\u2013664 (2014).","journal-title":"Eur. Heart J."},{"key":"339_CR65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF02066486","volume":"1","author":"S Nunoda","year":"1985","unstructured":"Nunoda, S. et al. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessel. 1, 43\u201347 (1985).","journal-title":"Heart Vessel."},{"key":"339_CR66","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2559.1989.tb02200.x","volume":"14","author":"CG Sutherland","year":"1989","unstructured":"Sutherland, C. G. et al. Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology 14, 593\u2013602 (1989).","journal-title":"Histopathology"},{"key":"339_CR67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jcp.46.1.32","volume":"46","author":"M Shimizu","year":"1993","unstructured":"Shimizu, M. et al. Collagen remodelling in myocardia of patients with diabetes. J. Clin. Pathol. 46, 32\u201336 (1993).","journal-title":"J. Clin. Pathol."},{"key":"339_CR68","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0046-8177(84)80307-X","volume":"15","author":"VW Fischer","year":"1984","unstructured":"Fischer, V. W., Barner, H. B. & Larose, L. S. Pathomorphologic aspects of muscular tissue in diabetes mellitus. Hum. Pathol. 15, 1127\u20131136 (1984).","journal-title":"Hum. Pathol."},{"key":"339_CR69","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/01.CIR.82.3.848","volume":"82","author":"KH van Hoeven","year":"1990","unstructured":"van Hoeven, K. H. & Factor, S. M. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 82, 848\u2013855 (1990).","journal-title":"Circulation"},{"key":"339_CR70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2840-8-58","volume":"8","author":"W Dinh","year":"2009","unstructured":"Dinh, W. et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc. Diabetol. 8, 58 (2009).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR71","doi-asserted-by":"crossref","first-page":"81ps17","DOI":"10.1126\/scitranslmed.3001902","volume":"3","author":"SL Masters","year":"2011","unstructured":"Masters, S. L., Latz, E. & O\u2019Neill, L. A. The inflammasome in atherosclerosis and type 2 diabetes. Sci. Transl Med. 3, 81ps17 (2011).","journal-title":"Sci. Transl Med."},{"key":"339_CR72","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/CIRCHEARTFAILURE.114.001963","volume":"8","author":"A Biernacka","year":"2015","unstructured":"Biernacka, A. et al. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ. Heart Fail. 8, 788\u2013798 (2015).","journal-title":"Circ. Heart Fail."},{"key":"339_CR73","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fphys.2018.01547","volume":"9","author":"A Bajpai","year":"2018","unstructured":"Bajpai, A. & Tilley, D. G. The role of leukocytes in diabetic cardiomyopathy. Front. Physiol. 9, 1547 (2018).","journal-title":"Front. Physiol."},{"key":"339_CR74","first-page":"32","volume":"46","author":"Y Lin","year":"2016","unstructured":"Lin, Y., Tang, Y. & Wang, F. The protective effect of HIF-1alpha in T lymphocytes on cardiac damage in diabetic mice. Ann. Clin. Lab. Sci. 46, 32\u201343 (2016).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"339_CR75","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.113.007101","volume":"129","author":"F Laroumanie","year":"2014","unstructured":"Laroumanie, F. et al. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation 129, 2111\u20132124 (2014).","journal-title":"Circulation"},{"key":"339_CR76","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/CIRCHEARTFAILURE.115.002225","volume":"8","author":"T Nevers","year":"2015","unstructured":"Nevers, T. et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ. Heart Fail. 8, 776\u2013787 (2015).","journal-title":"Circ. Heart Fail."},{"key":"339_CR77","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1096\/fj.201800231R","volume":"32","author":"CS Abdullah","year":"2018","unstructured":"Abdullah, C. S. & Jin, Z. Q. Targeted deletion of T-cell S1P receptor 1 ameliorates cardiac fibrosis in streptozotocin-induced diabetic mice. FASEB J. 32, 5426\u20135435 (2018).","journal-title":"FASEB J."},{"key":"339_CR78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.intimp.2016.07.027","volume":"39","author":"CS Abdullah","year":"2016","unstructured":"Abdullah, C. S., Li, Z., Wang, X. & Jin, Z. Q. Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy. Int. Immunopharmacol. 39, 251\u2013264 (2016).","journal-title":"Int. Immunopharmacol."},{"key":"339_CR79","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI6709","volume":"104","author":"S Frantz","year":"1999","unstructured":"Frantz, S. et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. 104, 271\u2013280 (1999).","journal-title":"J. Clin. Invest."},{"key":"339_CR80","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-8-133","volume":"8","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y. et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J. Transl Med. 8, 133 (2010).","journal-title":"J. Transl Med."},{"key":"339_CR81","doi-asserted-by":"crossref","first-page":"H732","DOI":"10.1152\/ajpheart.00948.2011","volume":"303","author":"B Dong","year":"2012","unstructured":"Dong, B. et al. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am. J. Physiol. Heart Circ. Physiol. 303, H732\u2013H742 (2012).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"339_CR82","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbadis.2015.07.015","volume":"1852","author":"A Tao","year":"2015","unstructured":"Tao, A. et al. Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: role of HMGB1\/TLR4\/IL-33 axis. Biochim. Biophys. Acta 1852, 2075\u20132085 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"339_CR83","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2. Nat. Commun. 8, 13997 (2017).","journal-title":"Nat. Commun."},{"key":"339_CR84","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbrc.2018.10.082","volume":"506","author":"L Lei","year":"2018","unstructured":"Lei, L., Hu, H., Lei, Y. & Feng, J. Leukocytic toll-like receptor 2 knockout protects against diabetes-induced cardiac dysfunction. Biochem. Biophys. Res. Commun. 506, 668\u2013673 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"339_CR85","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.bbadis.2017.01.010","volume":"1863","author":"N Hu","year":"2017","unstructured":"Hu, N. & Zhang, Y. TLR4 knockout attenuated high fat diet-induced cardiac dysfunction via NF-kappaB\/JNK-dependent activation of autophagy. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2001\u20132011 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"339_CR86","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.yjmcc.2018.04.009","volume":"119","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoRI-HDAC1-mediated regulation of autophagy. J. Mol. Cell Cardiol. 119, 40\u201350 (2018).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","volume":"61","author":"R Kokkola","year":"2005","unstructured":"Kokkola, R. et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61, 1\u20139 (2005).","journal-title":"Scand. J. Immunol."},{"key":"339_CR88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0030-1251503","volume":"36","author":"HC Volz","year":"2010","unstructured":"Volz, H. C., Kaya, Z., Katus, H. A. & Andrassy, M. The role of HMGB1\/RAGE in inflammatory cardiomyopathy. Semin. Thromb. Hemost. 36, 185\u2013194 (2010).","journal-title":"Semin. Thromb. Hemost."},{"key":"339_CR89","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00395-010-0114-3","volume":"105","author":"HC Volz","year":"2010","unstructured":"Volz, H. C. et al. HMGB1: the missing link between diabetes mellitus and heart failure. Basic. Res. Cardiol. 105, 805\u2013820 (2010).","journal-title":"Basic. Res. Cardiol."},{"key":"339_CR90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2079","volume":"7","author":"LA O'Neill","year":"2007","unstructured":"O\u2019Neill, L. A. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353\u2013364 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"339_CR91","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.4049\/jimmunol.180.7.5067","volume":"180","author":"JH Youn","year":"2008","unstructured":"Youn, J. H., Oh, Y. J., Kim, E. S., Choi, J. E. & Shin, J. S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-\u03b1 production in human monocytes. J. Immunol. 180, 5067\u20135074 (2008).","journal-title":"J. Immunol."},{"key":"339_CR92","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/eji.201141391","volume":"41","author":"JH Youn","year":"2011","unstructured":"Youn, J. H. et al. Identification of lipopolysaccharide-binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse model. Eur. J. Immunol. 41, 2753\u20132762 (2011).","journal-title":"Eur. J. Immunol."},{"key":"339_CR93","doi-asserted-by":"crossref","first-page":"172487","DOI":"10.1016\/j.ejphar.2019.172487","volume":"858","author":"YN Paudel","year":"2019","unstructured":"Paudel, Y. N. et al. Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: updates on receptor signalling. Eur. J. Pharmacol. 858, 172487 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"339_CR94","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijcard.2014.01.011","volume":"172","author":"WK Wang","year":"2014","unstructured":"Wang, W. K. et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int. J. Cardiol. 172, 202\u2013212 (2014).","journal-title":"Int. J. Cardiol."},{"key":"339_CR95","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387\u2013407 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"339_CR96","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/CIRCRESAHA.110.226928","volume":"108","author":"JW Gordon","year":"2011","unstructured":"Gordon, J. W., Shaw, J. A. & Kirshenbaum, L. A. Multiple facets of NF-\u03baB in the heart: to be or not to NF-\u03baB. Circ. Res. 108, 1122\u20131132 (2011).","journal-title":"Circ. Res."},{"key":"339_CR97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","volume":"62","author":"BW Van Tassell","year":"2013","unstructured":"Van Tassell, B. W., Seropian, I. M., Toldo, S., Mezzaroma, E. & Abbate, A. Interleukin-1\u03b2 induces a reversible cardiomyopathy in the mouse. Inflamm. Res. 62, 637\u2013640 (2013).","journal-title":"Inflamm. Res."},{"key":"339_CR98","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yjmcc.2018.01.001","volume":"115","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Ablation of interleukin-17 alleviated cardiac interstitial fibrosis and improved cardiac function via inhibiting long non-coding RNA-AK081284 in diabetic mice. J. Mol. Cell Cardiol. 115, 64\u201372 (2018).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/01.RES.0000255031.15793.86","volume":"100","author":"A Skyschally","year":"2007","unstructured":"Skyschally, A. et al. Bidirectional role of tumor necrosis factor-\u03b1 in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ. Res. 100, 140\u2013146 (2007).","journal-title":"Circ. Res."},{"key":"339_CR100","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.1074\/jbc.M212321200","volume":"278","author":"X Yu","year":"2003","unstructured":"Yu, X., Kennedy, R. H. & Liu, S. J. JAK2\/STAT3, not ERK1\/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J. Biol. Chem. 278, 16304\u201316309 (2003).","journal-title":"J. Biol. Chem."},{"key":"339_CR101","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.RES.0000150734.79804.92","volume":"95","author":"SD Prabhu","year":"2004","unstructured":"Prabhu, S. D. Cytokine-induced modulation of cardiac function. Circ. Res. 95, 1140\u20131153 (2004).","journal-title":"Circ. Res."},{"key":"339_CR102","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","volume":"119","author":"SD Prabhu","year":"2016","unstructured":"Prabhu, S. D. & Frangogiannis, N. G. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ. Res. 119, 91\u2013112 (2016).","journal-title":"Circ. Res."},{"key":"339_CR103","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jacc.2008.05.019","volume":"52","author":"G Zhou","year":"2008","unstructured":"Zhou, G. et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J. Am. Coll. Cardiol. 52, 655\u2013666 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR104","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s003950050007","volume":"95","author":"S Villegas","year":"2000","unstructured":"Villegas, S., Villarreal, F. J. & Dillmann, W. H. Leukemia inhibitory factor and interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes. Basic Res. Cardiol. 95, 47\u201354 (2000).","journal-title":"Basic Res. Cardiol."},{"key":"339_CR105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.RES.81.4.493","volume":"81","author":"CF McTiernan","year":"1997","unstructured":"McTiernan, C. F. et al. Interleukin-1\u03b2 inhibits phospholamban gene expression in cultured cardiomyocytes. Circ. Res. 81, 493\u2013503 (1997).","journal-title":"Circ. Res."},{"key":"339_CR106","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13344","volume":"7","author":"G Monnerat","year":"2016","unstructured":"Monnerat, G. et al. Macrophage-dependent IL-1\u03b2 production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7, 13344 (2016).","journal-title":"Nat. Commun."},{"key":"339_CR107","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGF\u03b21 and miR-29 pathways. Sci. Rep. 6, 23010 (2016).","journal-title":"Sci. Rep."},{"key":"339_CR108","doi-asserted-by":"crossref","first-page":"H1036","DOI":"10.1152\/ajpheart.00340.2014","volume":"307","author":"CM Thomas","year":"2014","unstructured":"Thomas, C. M. et al. Cardiac-specific suppression of NF-\u03baB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 307, H1036\u2013H1045 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"339_CR109","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He, Y., Hara, H. & Nunez, G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci. 41, 1012\u20131021 (2016).","journal-title":"Trends Biochem. Sci."},{"key":"339_CR110","volume":"9","author":"B Luo","year":"2014","unstructured":"Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One 9, e104771 (2014).","journal-title":"PLoS One"},{"key":"339_CR111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10557-013-6498-1","volume":"28","author":"B Luo","year":"2014","unstructured":"Luo, B. et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther. 28, 33\u201343 (2014).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"339_CR112","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fphar.2019.00719","volume":"10","author":"RG Snodgrass","year":"2019","unstructured":"Snodgrass, R. G. & Brune, B. Regulation and functions of 15-lipoxygenases in human macrophages. Front. Pharmacol. 10, 719 (2019).","journal-title":"Front. Pharmacol."},{"key":"339_CR113","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/db13-1896","volume":"64","author":"H Suzuki","year":"2015","unstructured":"Suzuki, H. et al. Arachidonate 12\/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes 64, 618\u2013630 (2015).","journal-title":"Diabetes"},{"key":"339_CR114","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.20082596","volume":"206","author":"Y Kayama","year":"2009","unstructured":"Kayama, Y. et al. Cardiac 12\/15 lipoxygenase-induced inflammation is involved in heart failure. J. Exp. Med. 206, 1565\u20131574 (2009).","journal-title":"J. Exp. Med."},{"key":"339_CR115","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","volume":"107","author":"RS Vasan","year":"2003","unstructured":"Vasan, R. S. et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107, 1486\u20131491 (2003).","journal-title":"Circulation"},{"key":"339_CR116","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.amjhyper.2007.01.023","volume":"20","author":"S Sciarretta","year":"2007","unstructured":"Sciarretta, S. et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am. J. Hypertens. 20, 784\u2013791 (2007).","journal-title":"Am. J. Hypertens."},{"key":"339_CR117","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCHEARTFAILURE.108.785485","volume":"1","author":"T Suzuki","year":"2008","unstructured":"Suzuki, T. et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health Study. Circ. Heart Fail. 1, 242\u2013248 (2008).","journal-title":"Circ. Heart Fail."},{"key":"339_CR118","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","volume":"51","author":"H Bahrami","year":"2008","unstructured":"Bahrami, H. et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J. Am. Coll. Cardiol. 51, 1775\u20131783 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR119","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/cvr\/cvx011","volume":"113","author":"G Frati","year":"2017","unstructured":"Frati, G. et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc. Res. 113, 378\u2013388 (2017).","journal-title":"Cardiovasc. Res."},{"key":"339_CR120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/CT:1:3:181","volume":"1","author":"L Cai","year":"2001","unstructured":"Cai, L. & Kang, Y. J. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 1, 181\u2013193 (2001).","journal-title":"Cardiovasc. Toxicol."},{"key":"339_CR121","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/heartjnl-2017-311448","volume":"104","author":"AJ Wilson","year":"2018","unstructured":"Wilson, A. J. et al. Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. Heart 104, 293\u2013299 (2018).","journal-title":"Heart"},{"key":"339_CR122","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787\u2013790 (2000).","journal-title":"Nature"},{"key":"339_CR123","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2337\/diabetes.54.6.1829","volume":"54","author":"L Cai","year":"2005","unstructured":"Cai, L. et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 54, 1829\u20131837 (2005).","journal-title":"Diabetes"},{"key":"339_CR124","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2337\/db10-1164","volume":"60","author":"Y Tan","year":"2011","unstructured":"Tan, Y. et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60, 625\u2013633 (2011).","journal-title":"Diabetes"},{"key":"339_CR125","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco, F. & Brownlee, M. Oxidative stress and diabetic complications. Circ. Res. 107, 1058\u20131070 (2010).","journal-title":"Circ. Res."},{"key":"339_CR126","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1089\/ars.2011.3999","volume":"15","author":"T Fukai","year":"2011","unstructured":"Fukai, T. & Ushio-Fukai, M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal. 15, 1583\u20131606 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"339_CR127","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.freeradbiomed.2015.11.013","volume":"90","author":"R Ni","year":"2016","unstructured":"Ni, R. et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free. Radic. Biol. Med. 90, 12\u201323 (2016).","journal-title":"Free. Radic. Biol. Med."},{"key":"339_CR128","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diabetes.55.03.06.db05-1039","volume":"55","author":"X Shen","year":"2006","unstructured":"Shen, X., Zheng, S., Metreveli, N. S. & Epstein, P. N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55, 798\u2013805 (2006).","journal-title":"Diabetes"},{"key":"339_CR129","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diabetes.53.5.1336","volume":"53","author":"G Ye","year":"2004","unstructured":"Ye, G. et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53, 1336\u20131343 (2004).","journal-title":"Diabetes"},{"key":"339_CR130","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2337\/diabetes.51.1.174","volume":"51","author":"Q Liang","year":"2002","unstructured":"Liang, Q. et al. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 51, 174\u2013181 (2002).","journal-title":"Diabetes"},{"key":"339_CR131","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2006.07.022","volume":"48","author":"L Cai","year":"2006","unstructured":"Cai, L. et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 48, 1688\u20131697 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yjmcc.2008.10.007","volume":"46","author":"X He","year":"2009","unstructured":"He, X., Kan, H., Cai, L. & Ma, Q. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J. Mol. Cell Cardiol. 46, 47\u201358 (2009).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR133","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.redox.2017.12.016","volume":"15","author":"Y Xin","year":"2018","unstructured":"Xin, Y. et al. Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt\/GSK-3ss\/Fyn pathway. Redox Biol. 15, 405\u2013417 (2018).","journal-title":"Redox Biol."},{"key":"339_CR134","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db15-1274","volume":"66","author":"J Gu","year":"2017","unstructured":"Gu, J. et al. Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy. Diabetes 66, 529\u2013542 (2017).","journal-title":"Diabetes"},{"key":"339_CR135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2337\/dc06-1682","volume":"30","author":"M Soinio","year":"2007","unstructured":"Soinio, M. et al. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 30, 523\u2013528 (2007).","journal-title":"Diabetes Care"},{"key":"339_CR136","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cardfail.2018.02.011","volume":"24","author":"A Yoshihisa","year":"2018","unstructured":"Yoshihisa, A. et al. Association of serum zinc level with prognosis in patients with heart failure. J. Card. Fail. 24, 375\u2013383 (2018).","journal-title":"J. Card. Fail."},{"key":"339_CR137","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.hlc.2017.01.022","volume":"27","author":"L Huang","year":"2018","unstructured":"Huang, L. et al. The relationship between serum zinc levels, cardiac markers and the risk of acute myocardial infarction by zinc quartiles. Heart Lung Circ. 27, 66\u201372 (2018).","journal-title":"Heart Lung Circ."},{"key":"339_CR138","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s11695-010-0237-5","volume":"20","author":"A Salle","year":"2010","unstructured":"Salle, A. et al. Zinc deficiency: a frequent and underestimated complication after bariatric surgery. Obes. Surg. 20, 1660\u20131670 (2010).","journal-title":"Obes. Surg."},{"key":"339_CR139","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s11695-016-2474-8","volume":"27","author":"KK Mahawar","year":"2017","unstructured":"Mahawar, K. K. et al. Zinc deficiency after gastric bypass for morbid obesity: a systematic review. Obes. Surg. 27, 522\u2013529 (2017).","journal-title":"Obes. Surg."},{"key":"339_CR140","first-page":"397","volume":"89","author":"S Ripa","year":"1998","unstructured":"Ripa, S., Ripa, R. & Giustiniani, S. Are failured cardiomyopathies a zinc-deficit related disease? A study on Zn and Cu in patients with chronic failured dilated and hypertrophic cardiomyopathies. Minerva Med. 89, 397\u2013403 (1998).","journal-title":"Minerva Med."},{"key":"339_CR141","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/eurjhf\/hfr167","volume":"14","author":"A Frustaci","year":"2012","unstructured":"Frustaci, A. et al. Selenium- and zinc-deficient cardiomyopathy in human intestinal malabsorption: preliminary results of selenium\/zinc infusion. Eur. J. Heart Fail. 14, 202\u2013210 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR142","doi-asserted-by":"publisher","unstructured":"Cao, J. W., Duan, S. Y., Zhang, H. X., Chen, Y. & Guo, M. Zinc deficiency promoted fibrosis via ROS and TIMP\/MMPs in the myocardium of mice. Biol. Trace Elem. Res. https:\/\/doi.org\/10.1007\/s12011-019-01902-4 (2019).","DOI":"10.1007\/s12011-019-01902-4"},{"key":"339_CR143","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/cvr\/cvn093","volume":"79","author":"L Bertrand","year":"2008","unstructured":"Bertrand, L., Horman, S., Beauloye, C. & Vanoverschelde, J. L. Insulin signalling in the heart. Cardiovasc. Res. 79, 238\u2013248 (2008).","journal-title":"Cardiovasc. Res."},{"key":"339_CR144","doi-asserted-by":"crossref","first-page":"65A","DOI":"10.1016\/S0002-9149(97)00459-1","volume":"80","author":"A Zorzano","year":"1997","unstructured":"Zorzano, A. et al. Regulation of glucose transport, and glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. Am. J. Cardiol. 80, 65A\u201376A (1997).","journal-title":"Am. J. Cardiol."},{"key":"339_CR145","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2741\/1216","volume":"9","author":"ED Abel","year":"2004","unstructured":"Abel, E. D. Glucose transport in the heart. Front. Biosci. 9, 201\u2013215 (2004).","journal-title":"Front. Biosci."},{"key":"339_CR146","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1074\/jbc.272.11.7085","volume":"272","author":"Y Fischer","year":"1997","unstructured":"Fischer, Y. et al. Insulin-induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. Evidence of the existence of different intracellular GLUT4 vesicle populations. J. Biol. Chem. 272, 7085\u20137092 (1997).","journal-title":"J. Biol. Chem."},{"key":"339_CR147","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1152\/ajpendo.2001.280.1.E65","volume":"280","author":"A Kessler","year":"2001","unstructured":"Kessler, A., Uphues, I., Ouwens, D. M., Till, M. & Eckel, J. Diversification of cardiac insulin signaling involves the p85\u03b1\/\u03b2 subunits of phosphatidylinositol 3-kinase. Am. J. Physiol. Endocrinol. Metab. 280, E65\u2013E74 (2001).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"339_CR148","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2337\/diabetes.51.10.3113","volume":"51","author":"JJ Luiken","year":"2002","unstructured":"Luiken, J. J. et al. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT\/CD36. Diabetes 51, 3113\u20133119 (2002).","journal-title":"Diabetes"},{"key":"339_CR149","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/diabetes.52.7.1627","volume":"52","author":"JJ Luiken","year":"2003","unstructured":"Luiken, J. J. et al. Contraction-induced fatty acid translocase\/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52, 1627\u20131634 (2003).","journal-title":"Diabetes"},{"key":"339_CR150","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1194\/jlr.R082933","volume":"59","author":"JFC Glatz","year":"2018","unstructured":"Glatz, J. F. C. & Luiken, J. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. J. Lipid Res. 59, 1084\u20131093 (2018).","journal-title":"J. Lipid Res."},{"key":"339_CR151","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s00125-007-0735-8","volume":"50","author":"DM Ouwens","year":"2007","unstructured":"Ouwens, D. M. et al. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50, 1938\u20131948 (2007).","journal-title":"Diabetologia"},{"key":"339_CR152","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/BJ20120060","volume":"448","author":"Y Angin","year":"2012","unstructured":"Angin, Y. et al. CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Biochem. J. 448, 43\u201353 (2012).","journal-title":"Biochem. J."},{"key":"339_CR153","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-016-0309-5","volume":"24","author":"TW Lee","year":"2017","unstructured":"Lee, T. W. et al. PPARs modulate cardiac metabolism and mitochondrial function in diabetes. J. Biomed. Sci. 24, 5 (2017).","journal-title":"J. Biomed. Sci."},{"key":"339_CR154","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"BN Finck","year":"2002","unstructured":"Finck, B. N. et al. The cardiac phenotype induced by PPAR\u03b1 overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121\u2013130 (2002).","journal-title":"J. Clin. Invest."},{"key":"339_CR155","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.RES.0000264104.25265.b6","volume":"100","author":"J Yang","year":"2007","unstructured":"Yang, J. et al. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ. Res. 100, 1208\u20131217 (2007).","journal-title":"Circ. Res."},{"key":"339_CR156","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/db17-0219","volume":"67","author":"J Gu","year":"2018","unstructured":"Gu, J. et al. Metallothionein preserves Akt2 activity and cardiac function via inhibiting TRB3 in diabetic hearts. Diabetes 67, 507\u2013517 (2018).","journal-title":"Diabetes"},{"key":"339_CR157","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","volume":"31","author":"SA Cook","year":"2010","unstructured":"Cook, S. A. et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 31, 100\u2013111 (2010).","journal-title":"Eur. Heart J."},{"key":"339_CR158","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/cvr\/cvp017","volume":"82","author":"JJ Wright","year":"2009","unstructured":"Wright, J. J. et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc. Res. 82, 351\u2013360 (2009).","journal-title":"Cardiovasc. Res."},{"key":"339_CR159","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12933-017-0643-2","volume":"17","author":"E Ramirez","year":"2018","unstructured":"Ramirez, E. et al. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking. Cardiovasc. Diabetol. 17, 12 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR160","doi-asserted-by":"crossref","first-page":"H1098","DOI":"10.1152\/ajpheart.00101.2017","volume":"313","author":"AR Wende","year":"2017","unstructured":"Wende, A. R. et al. Glucose transporter 4-deficient hearts develop maladaptive hypertrophy in response to physiological or pathological stresses. Am. J. Physiol. Heart Circ. Physiol. 313, H1098\u2013H1108 (2017).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"339_CR161","doi-asserted-by":"crossref","first-page":"38349","DOI":"10.1074\/jbc.C100462200","volume":"276","author":"H Cho","year":"2001","unstructured":"Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1\/PKB\u03b1 is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349\u201338352 (2001).","journal-title":"J. Biol. Chem."},{"key":"339_CR162","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1074\/jbc.273.13.7201","volume":"273","author":"MR Calera","year":"1998","unstructured":"Calera, M. R. et al. Insulin increases the association of Akt-2 with Glut4-containing vesicles. J. Biol. Chem. 273, 7201\u20137204 (1998).","journal-title":"J. Biol. Chem."},{"key":"339_CR163","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1128\/MCB.00722-06","volume":"26","author":"B Dummler","year":"2006","unstructured":"Dummler, B. et al. Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell Biol. 26, 8042\u20138051 (2006).","journal-title":"Mol. Cell Biol."},{"key":"339_CR164","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1126\/science.292.5522.1728","volume":"292","author":"H Cho","year":"2001","unstructured":"Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB\u03b2). Science 292, 1728\u20131731 (2001).","journal-title":"Science"},{"key":"339_CR165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI16885","volume":"112","author":"RS Garofalo","year":"2003","unstructured":"Garofalo, R. S. et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2\/PKB\u03b2. J. Clin. Invest. 112, 197\u2013208 (2003).","journal-title":"J. Clin. Invest."},{"key":"339_CR166","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","volume":"9","author":"CY Chen","year":"2018","unstructured":"Chen, C. Y., Chen, J., He, L. & Stiles, B. L. PTEN: tumor suppressor and metabolic regulator. Front. Endocrinol. 9, 338 (2018).","journal-title":"Front. Endocrinol."},{"key":"339_CR167","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/diabetes.52.1.21","volume":"52","author":"RJ Gum","year":"2003","unstructured":"Gum, R. J. et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob\/ob mice. Diabetes 52, 21\u201328 (2003).","journal-title":"Diabetes"},{"key":"339_CR168","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1126\/science.1079817","volume":"300","author":"K Du","year":"2003","unstructured":"Du, K., Herzig, S., Kulkarni, R. N. & Montminy, M. TRB3: a tribbles homolog that inhibits Akt\/PKB activation by insulin in liver. Science 300, 1574\u20131577 (2003).","journal-title":"Science"},{"key":"339_CR169","volume":"4","author":"HJ Koh","year":"2013","unstructured":"Koh, H. J. et al. Tribbles 3 mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle. Nat. Commun. 4, 1871 (2013).","journal-title":"Nat. Commun."},{"key":"339_CR170","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.25.6.2498-2510.2005","volume":"25","author":"C Kurlawalla-Martinez","year":"2005","unstructured":"Kurlawalla-Martinez, C. et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol. Cell Biol. 25, 2498\u20132510 (2005).","journal-title":"Mol. Cell Biol."},{"key":"339_CR171","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1073\/pnas.0308617100","volume":"101","author":"B Stiles","year":"2004","unstructured":"Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl Acad. Sci. USA 101, 2082\u20132087 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"339_CR172","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/MCB.25.3.1135-1145.2005","volume":"25","author":"N Wijesekara","year":"2005","unstructured":"Wijesekara, N. et al. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol. Cell Biol. 25, 1135\u20131145 (2005).","journal-title":"Mol. Cell Biol."},{"key":"339_CR173","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/cvr\/cvn041","volume":"78","author":"GY Oudit","year":"2008","unstructured":"Oudit, G. Y. et al. Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovasc. Res. 78, 505\u2013514 (2008).","journal-title":"Cardiovasc. Res."},{"key":"339_CR174","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yjmcc.2008.10.021","volume":"46","author":"H Ruan","year":"2009","unstructured":"Ruan, H. et al. Inducible and cardiac specific PTEN inactivation protects ischemia\/reperfusion injury. J. Mol. Cell Cardiol. 46, 193\u2013200 (2009).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR175","volume":"10","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3\u03b2 and mitochondrial function. BMC Med. 10, 40 (2012).","journal-title":"BMC Med."},{"key":"339_CR176","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1126\/science.283.5407.1544","volume":"283","author":"M Elchebly","year":"1999","unstructured":"Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544\u20131548 (1999).","journal-title":"Science"},{"key":"339_CR177","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1128\/MCB.00959-07","volume":"27","author":"M Delibegovic","year":"2007","unstructured":"Delibegovic, M. et al. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B. Mol. Cell Biol. 27, 7727\u20137734 (2007).","journal-title":"Mol. Cell Biol."},{"key":"339_CR178","volume":"7","author":"TD Nguyen","year":"2018","unstructured":"Nguyen, T. D. et al. Increased protein tyrosine phosphatase 1B (PTP1B) activity and cardiac insulin resistance precede mitochondrial and contractile dysfunction in pressure-overloaded hearts. J. Am. Heart Assoc. 7, e008865 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"339_CR179","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbadis.2014.07.004","volume":"1852","author":"MR Kandadi","year":"2015","unstructured":"Kandadi, M. R. et al. Deletion of protein tyrosine phosphatase 1B rescues against myocardial anomalies in high fat diet-induced obesity: role of AMPK-dependent autophagy. Biochim. Biophys. Acta 1852, 299\u2013309 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"339_CR180","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1096\/fj.13-245753","volume":"28","author":"M Besnier","year":"2014","unstructured":"Besnier, M. et al. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice. FASEB J. 28, 3351\u20133361 (2014).","journal-title":"FASEB J."},{"key":"339_CR181","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.2337\/db11-0549","volume":"60","author":"Y Ti","year":"2011","unstructured":"Ti, Y. et al. TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes 60, 2963\u20132974 (2011).","journal-title":"Diabetes"},{"key":"339_CR182","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1159\/000492264","volume":"48","author":"M Kwon","year":"2018","unstructured":"Kwon, M. et al. Skeletal muscle tissue Trib3 links obesity with insulin resistance by autophagic degradation of AKT2. Cell Physiol. Biochem. 48, 1543\u20131555 (2018).","journal-title":"Cell Physiol. Biochem."},{"key":"339_CR183","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1161\/CIRCRESAHA.109.211920","volume":"106","author":"J Avery","year":"2010","unstructured":"Avery, J. et al. TRB3 function in cardiac endoplasmic reticulum stress. Circ. Res. 106, 1516\u20131523 (2010).","journal-title":"Circ. Res."},{"key":"339_CR184","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1016\/j.bmcl.2009.09.120","volume":"19","author":"SC Zammit","year":"2009","unstructured":"Zammit, S. C. et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg. Med. Chem. Lett. 19, 7003\u20137006 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"339_CR185","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/eurjhf\/hfs011","volume":"14","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur. J. Heart Fail. 14, 549\u2013562 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR186","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1440-1681.2012.05726.x","volume":"39","author":"SM Tan","year":"2012","unstructured":"Tan, S. M. et al. FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy. Clin. Exp. Pharmacol. Physiol. 39, 650\u2013656 (2012).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"339_CR187","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ijcard.2012.11.067","volume":"168","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. Int. J. Cardiol. 168, 1174\u20131185 (2013).","journal-title":"Int. J. Cardiol."},{"key":"339_CR188","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000536","volume":"2","author":"SJ Greene","year":"2013","unstructured":"Greene, S. J. et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J. Am. Heart Assoc. 2, e000536 (2013).","journal-title":"J. Am. Heart Assoc."},{"key":"339_CR189","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tips.2014.05.003","volume":"35","author":"R Lukowski","year":"2014","unstructured":"Lukowski, R., Krieg, T., Rybalkin, S. D., Beavo, J. & Hofmann, F. Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. Trends Pharmacol. Sci. 35, 404\u2013413 (2014).","journal-title":"Trends Pharmacol. Sci."},{"key":"339_CR190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejphar.2018.12.002","volume":"844","author":"MK Derici","year":"2019","unstructured":"Derici, M. K., Sadi, G., Cenik, B., Guray, T. & Demirel-Yilmaz, E. Differential expressions and functions of phosphodiesterase enzymes in different regions of the rat heart. Eur. J. Pharmacol. 844, 118\u2013129 (2019).","journal-title":"Eur. J. Pharmacol."},{"key":"339_CR191","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCHEARTFAILURE.111.961706","volume":"5","author":"X Shan","year":"2012","unstructured":"Shan, X. et al. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ. Heart Fail. 5, 79\u201386 (2012).","journal-title":"Circ. Heart Fail."},{"key":"339_CR192","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2013.01.031","volume":"60","author":"S Koka","year":"2013","unstructured":"Koka, S., Das, A., Salloum, F. N. & Kukreja, R. C. Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia\/reperfusion injury in type 2 diabetic mice. Free. Radic. Biol. Med. 60, 80\u201388 (2013).","journal-title":"Free. Radic. Biol. Med."},{"key":"339_CR193","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1042\/CS20190585","volume":"133","author":"M Xue","year":"2019","unstructured":"Xue, M. et al. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice. Clin. Sci. 133, 1705\u20131720 (2019).","journal-title":"Clin. Sci."},{"key":"339_CR194","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/er.2003-0013","volume":"25","author":"OD Sherwood","year":"2004","unstructured":"Sherwood, O. D. Relaxin\u2019s physiological roles and other diverse actions. Endocr. Rev. 25, 205\u2013234 (2004).","journal-title":"Endocr. Rev."},{"key":"339_CR195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","volume":"487","author":"B Martin","year":"2019","unstructured":"Martin, B., Romero, G. & Salama, G. Cardioprotective actions of relaxin. Mol. Cell Endocrinol. 487, 45\u201353 (2019).","journal-title":"Mol. Cell Endocrinol."},{"key":"339_CR196","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/en.2004-0209","volume":"145","author":"CS Samuel","year":"2004","unstructured":"Samuel, C. S. et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145, 4125\u20134133 (2004).","journal-title":"Endocrinology"},{"key":"339_CR197","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1196\/annals.1282.028","volume":"1041","author":"I Mookerjee","year":"2005","unstructured":"Mookerjee, I., Unemori, E. N., Du, X. J., Tregear, G. W. & Samuel, C. S. Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann. N. Y. Acad. Sci. 1041, 190\u2013193 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"339_CR198","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063896","volume":"8","author":"C Sassoli","year":"2013","unstructured":"Sassoli, C. et al. Relaxin prevents cardiac fibroblast-myofibroblast transition via Notch-1-mediated inhibition of TGF-\u03b2\/Smad3 signaling. PLoS One 8, e63896 (2013).","journal-title":"PLoS One"},{"key":"339_CR199","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1196\/annals.1282.025","volume":"1041","author":"CS Samuel","year":"2005","unstructured":"Samuel, C. S. et al. The relaxin gene-knockout mouse: a model of progressive fibrosis. Ann. N. Y. Acad. Sci. 1041, 173\u2013181 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"339_CR200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00441-017-2662-4","volume":"370","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats. Cell Tissue Res. 370, 297\u2013304 (2017).","journal-title":"Cell Tissue Res."},{"key":"339_CR201","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","volume":"149","author":"CS Samuel","year":"2008","unstructured":"Samuel, C. S., Hewitson, T. D., Zhang, Y. & Kelly, D. J. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology 149, 3286\u20133293 (2008).","journal-title":"Endocrinology"},{"key":"339_CR202","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1159\/000481843","volume":"43","author":"X Zhang","year":"2017","unstructured":"Zhang, X. et al. H3 relaxin protects against myocardial injury in experimental diabetic cardiomyopathy by inhibiting myocardial apoptosis, fibrosis and inflammation. Cell Physiol. Biochem. 43, 1311\u20131324 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"339_CR203","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0043-116946","volume":"126","author":"P Wang","year":"2018","unstructured":"Wang, P. et al. Relaxin Inhibits cardiac fibrosis in diabetic rats: roles of protein kinase C\u03b4. Exp. Clin. Endocrinol. Diabetes 126, 298\u2013305 (2018).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"339_CR204","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2007.09.008","volume":"280","author":"RA Bathgate","year":"2008","unstructured":"Bathgate, R. A. et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol. Cell Endocrinol. 280, 30\u201338 (2008).","journal-title":"Mol. Cell Endocrinol."},{"key":"339_CR205","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","volume":"125","author":"E Giannetta","year":"2012","unstructured":"Giannetta, E. et al. Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125, 2323\u20132333 (2012).","journal-title":"Circulation"},{"key":"339_CR206","first-page":"1238","volume":"39","author":"L Di Luigi","year":"2016","unstructured":"Di Luigi, L. et al. Phosphodiesterase type 5 inhibitor sildenafil decreases the proinflammatory chemokine CXCL10 in human cardiomyocytes and in subjects with diabetic cardiomyopathy. Inflammation 39, 1238\u20131252 (2016).","journal-title":"Inflammation"},{"key":"339_CR207","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40618-018-0977-y","volume":"42","author":"S Giannattasio","year":"2019","unstructured":"Giannattasio, S. et al. The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. J. Endocrinol. Invest. 42, 715\u2013725 (2019).","journal-title":"J. Endocrinol. Invest."},{"key":"339_CR208","doi-asserted-by":"crossref","first-page":"E2882","DOI":"10.3390\/ijms19102882","volume":"19","author":"D Priksz","year":"2018","unstructured":"Priksz, D. et al. Upregulation of myocardial and vascular phosphodiesterase 9A in a model of atherosclerotic cardiovascular disease. Int J Mol Sci 19, E2882 (2018).","journal-title":"Int J Mol Sci"},{"key":"339_CR209","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature14332","volume":"519","author":"DI Lee","year":"2015","unstructured":"Lee, D. I. et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519, 472\u2013476 (2015).","journal-title":"Nature"},{"key":"339_CR210","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","volume":"33","author":"J Chun","year":"2010","unstructured":"Chun, J. & Hartung, H. P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 33, 91\u2013101 (2010).","journal-title":"Clin. Neuropharmacol."},{"key":"339_CR211","volume":"7","author":"Z Yin","year":"2012","unstructured":"Yin, Z. et al. FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1\/3 in diabetic heart disease. PLoS One 7, e42900 (2012).","journal-title":"PLoS One"},{"key":"339_CR212","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1253\/circj.CJ-14-0521","volume":"78","author":"H Xu","year":"2014","unstructured":"Xu, H., Jin, Y., Ni, H., Hu, S. & Zhang, Q. Sphingosine-1-phosphate receptor agonist, FTY720, restores coronary flow reserve in diabetic rats. Circ. J. 78, 2979\u20132986 (2014).","journal-title":"Circ. J."},{"key":"339_CR213","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/aps.2014.127","volume":"36","author":"ZW Liu","year":"2015","unstructured":"Liu, Z. W. et al. Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS\/TLR-4 signaling pathway. Acta Pharmacol. Sin. 36, 323\u2013333 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"339_CR214","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jep.2016.08.029","volume":"193","author":"X Guo","year":"2016","unstructured":"Guo, X. et al. Protective effects of triptolide on TLR4 mediated autoimmune and inflammatory response induced myocardial fibrosis in diabetic cardiomyopathy. J. Ethnopharmacol. 193, 333\u2013344 (2016).","journal-title":"J. Ethnopharmacol."},{"key":"339_CR215","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jsxm.2018.07.005","volume":"15","author":"KP Nunes","year":"2018","unstructured":"Nunes, K. P., de Oliveira, A. A., Szasz, T., Biancardi, V. C. & Webb, R. C. Blockade of toll-like receptor 4 attenuates erectile dysfunction in diabetic rats. J. Sex. Med. 15, 1235\u20131245 (2018).","journal-title":"J. Sex. Med."},{"key":"339_CR216","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s00395-007-0673-0","volume":"102","author":"D Westermann","year":"2007","unstructured":"Westermann, D. et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic. Res. Cardiol. 102, 500\u2013507 (2007).","journal-title":"Basic. Res. Cardiol."},{"key":"339_CR217","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12933-015-0288-y","volume":"14","author":"Z Liu","year":"2015","unstructured":"Liu, Z. et al. Circulating interleukin-1\u03b2 promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2. Cardiovasc. Diabetol. 14, 125 (2015).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR218","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FJC.0000000000000628","volume":"72","author":"S Carbone","year":"2018","unstructured":"Carbone, S. et al. An orally available NLRP3 inflammasome inhibitor prevents western diet-induced cardiac dysfunction in mice. J. Cardiovasc. Pharmacol. 72, 303\u2013307 (2018).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"339_CR219","first-page":"828","volume":"38","author":"GP van Hout","year":"2017","unstructured":"van Hout, G. P. et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur. Heart J. 38, 828\u2013836 (2017).","journal-title":"Eur. Heart J."},{"key":"339_CR220","doi-asserted-by":"crossref","first-page":"99740","DOI":"10.18632\/oncotarget.20763","volume":"8","author":"LE Pavillard","year":"2017","unstructured":"Pavillard, L. E. et al. NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction. Oncotarget 8, 99740\u201399756 (2017).","journal-title":"Oncotarget"},{"key":"339_CR221","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2147\/DMSO.S199802","volume":"12","author":"C Zhang","year":"2019","unstructured":"Zhang, C. et al. A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation. Diabetes Metab. Syndr. Obes. 12, 1297\u20131309 (2019).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"339_CR222","doi-asserted-by":"crossref","first-page":"850","DOI":"10.14336\/AD.2017.0829","volume":"8","author":"W Liang","year":"2017","unstructured":"Liang, W., Huang, X. & Chen, W. The effects of baicalin and baicalein on cerebral ischemia: a review. Aging Dis. 8, 850\u2013867 (2017).","journal-title":"Aging Dis."},{"key":"339_CR223","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.biopha.2017.07.068","volume":"93","author":"B Bie","year":"2017","unstructured":"Bie, B. et al. Baicalein: a review of its anti-cancer effects and mechanisms in hepatocellular carcinoma. Biomed. Pharmacother. 93, 1285\u20131291 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"339_CR224","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajh\/hpu194","volume":"28","author":"AW Wang","year":"2015","unstructured":"Wang, A. W. et al. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT\/mTOR, ERK1\/2, NF-\u03baB, and calcineurin signaling pathways in mice. Am. J. Hypertens. 28, 518\u2013526 (2015).","journal-title":"Am. J. Hypertens."},{"key":"339_CR225","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/eurjhf\/hfr035","volume":"13","author":"H Ehrentraut","year":"2011","unstructured":"Ehrentraut, H. et al. The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur. J. Heart Fail. 13, 602\u2013610 (2011).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR226","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","volume":"38","author":"TW Rice","year":"2010","unstructured":"Rice, T. W. et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit. Care Med. 38, 1685\u20131694 (2010).","journal-title":"Crit. Care Med."},{"key":"339_CR227","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","volume":"309","author":"SM Opal","year":"2013","unstructured":"Opal, S. M. et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309, 1154\u20131162 (2013).","journal-title":"JAMA"},{"key":"339_CR228","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt.522","volume":"101","author":"E Monnet","year":"2017","unstructured":"Monnet, E. et al. Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS. Clin. Pharmacol. Ther. 101, 200\u2013208 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"339_CR229","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03241108?term=NCT03241108&draw=2&rank=1 (2018)."},{"key":"339_CR230","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M. et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739\u20132748 (2012).","journal-title":"Circulation"},{"key":"339_CR231","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"339_CR232","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","volume":"139","author":"BM Everett","year":"2019","unstructured":"Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation 139, 1289\u20131299 (2019).","journal-title":"Circulation"},{"key":"339_CR233","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","volume":"71","author":"BM Everett","year":"2018","unstructured":"Everett, B. M. et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J. Am. Coll. Cardiol. 71, 2392\u20132401 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR234","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/eurheartj\/ehx246","volume":"38","author":"A Bayes-Genis","year":"2017","unstructured":"Bayes-Genis, A., Adler, Y., de Luna, A. B. & Imazio, M. Colchicine in pericarditis. Eur. Heart J. 38, 1706\u20131709 (2017).","journal-title":"Eur. Heart J."},{"key":"339_CR235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237\u2013241 (2006).","journal-title":"Nature"},{"key":"339_CR236","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2018.11.016","volume":"41","author":"SM Nidorf","year":"2019","unstructured":"Nidorf, S. M. & Thompson, P. L. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin. Ther. 41, 41\u201348 (2019).","journal-title":"Clin. Ther."},{"key":"339_CR237","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","volume":"11","author":"K Vaidya","year":"2018","unstructured":"Vaidya, K. et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovasc. Imaging 11, 305\u2013316 (2018).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"339_CR238","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/dom.13702","volume":"21","author":"AP Demidowich","year":"2019","unstructured":"Demidowich, A. P. et al. Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. Diabetes Obes. Metab. 21, 1642\u20131651 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"339_CR239","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02035891?term=NCT02035891&draw=2&rank=1 (2019)."},{"key":"339_CR240","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03376698?term=NCT03376698&draw=2&rank=1 (2019)."},{"key":"339_CR241","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0278-6915(99)00082-4","volume":"37","author":"JW Fahey","year":"1999","unstructured":"Fahey, J. W. & Talalay, P. Antioxidant functions of sulforaphane: a potent inducer of phase II detoxication enzymes. Food Chem. Toxicol. 37, 973\u2013979 (1999).","journal-title":"Food Chem. Toxicol."},{"key":"339_CR242","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yjmcc.2013.01.008","volume":"57","author":"Y Bai","year":"2013","unstructured":"Bai, Y. et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell Cardiol. 57, 82\u201395 (2013).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR243","volume":"6","author":"Z Xu","year":"2016","unstructured":"Xu, Z. et al. Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db\/db T2DM mice. Sci. Rep. 6, 30252 (2016).","journal-title":"Sci. Rep."},{"key":"339_CR244","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.yjmcc.2014.09.022","volume":"77","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z. et al. Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1\/AMPK pathway. J. Mol. Cell Cardiol. 77, 42\u201352 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"key":"339_CR245","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cardiores.2006.11.033","volume":"73","author":"Z Xia","year":"2007","unstructured":"Xia, Z. et al. N-acetylcysteine attenuates PKC\u03b22 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc. Res. 73, 770\u2013782 (2007).","journal-title":"Cardiovasc. Res."},{"key":"339_CR246","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12872-015-0076-3","volume":"15","author":"C Liu","year":"2015","unstructured":"Liu, C. et al. N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition. BMC Cardiovasc. Disord. 15, 84 (2015).","journal-title":"BMC Cardiovasc. Disord."},{"key":"339_CR247","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3109\/10715762.2011.605361","volume":"45","author":"T Okazaki","year":"2011","unstructured":"Okazaki, T. et al. Ascorbic acid and N-acetyl cysteine prevent uncoupling of nitric oxide synthase and increase tolerance to ischemia\/reperfusion injury in diabetic rat heart. Free. Radic. Res. 45, 1173\u20131183 (2011).","journal-title":"Free. Radic. Res."},{"key":"339_CR248","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12933-016-0460-z","volume":"15","author":"W Su","year":"2016","unstructured":"Su, W. et al. N-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3\/eNOS signaling in diabetic rats. Cardiovasc. Diabetol. 15, 146 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR249","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.105.537894","volume":"113","author":"J Wang","year":"2006","unstructured":"Wang, J. et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113, 544\u2013554 (2006).","journal-title":"Circulation"},{"key":"339_CR250","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1039\/C7MT00210F","volume":"9","author":"S Barman","year":"2017","unstructured":"Barman, S., Pradeep, S. R. & Srinivasan, K. Zinc supplementation mitigates its dyshomeostasis in experimental diabetic rats by regulating the expression of zinc transporters and metallothionein. Metallomics 9, 1765\u20131777 (2017).","journal-title":"Metallomics"},{"key":"339_CR251","doi-asserted-by":"crossref","first-page":"E580","DOI":"10.3390\/ijms18030580","volume":"18","author":"S Wang","year":"2017","unstructured":"Wang, S. et al. Zinc prevents the development of diabetic cardiomyopathy in db\/db mice. Int. J. Mol. Sci. 18, E580 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"339_CR252","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12933-016-0383-8","volume":"15","author":"S Korkmaz-Icoz","year":"2016","unstructured":"Korkmaz-Icoz, S. et al. Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway. Cardiovasc. Diabetol. 15, 75 (2016).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR253","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12011-014-9923-9","volume":"158","author":"F Liu","year":"2014","unstructured":"Liu, F. et al. Zinc supplementation alleviates diabetic peripheral neuropathy by inhibiting oxidative stress and upregulating metallothionein in peripheral nerves of diabetic rats. Biol. Trace Elem. Res. 158, 211\u2013218 (2014).","journal-title":"Biol. Trace Elem. Res."},{"key":"339_CR254","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0038-1666848","volume":"28","author":"M Yahalom","year":"2019","unstructured":"Yahalom, M., Koren, O., Rozner, E. & Turgeman, Y. Cardiomyopathy associated with zinc deficiency after bariatric surgery. Int. J. Angiol. 28, 145\u2013146 (2019).","journal-title":"Int. J. Angiol."},{"key":"339_CR255","doi-asserted-by":"crossref","first-page":"E987","DOI":"10.1152\/ajpendo.90234.2008","volume":"294","author":"L Yang","year":"2008","unstructured":"Yang, L. et al. Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am. J. Physiol. Endocrinol. Metab. 294, E987\u2013E992 (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"339_CR256","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2007.12.006","volume":"94","author":"R Giacconi","year":"2008","unstructured":"Giacconi, R. et al. +647 A\/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol. Genet. Metab. 94, 98\u2013104 (2008).","journal-title":"Mol. Genet. Metab."},{"key":"339_CR257","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10534-017-9996-y","volume":"30","author":"GB de Carvalho","year":"2017","unstructured":"de Carvalho, G. B., Brandao-Lima, P. N., Maia, C. S., Barbosa, K. B. & Pires, L. V. Zinc\u2019s role in the glycemic control of patients with type 2 diabetes: a systematic review. Biometals 30, 151\u2013162 (2017).","journal-title":"Biometals"},{"key":"339_CR258","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2119\/2007-00045.Giacconi","volume":"13","author":"R Giacconi","year":"2007","unstructured":"Giacconi, R. et al. The +838 C\/G MT2A polymorphism, metals, and the inflammatory\/immune response in carotid artery stenosis in elderly people. Mol. Med. 13, 388\u2013395 (2007).","journal-title":"Mol. Med."},{"key":"339_CR259","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10522-011-9337-4","volume":"12","author":"E Mocchegiani","year":"2011","unstructured":"Mocchegiani, E. et al. Zinc, metallothioneins and immunosenescence: effect of zinc supply as nutrigenomic approach. Biogerontology 12, 455\u2013465 (2011).","journal-title":"Biogerontology"},{"key":"339_CR260","doi-asserted-by":"crossref","first-page":"12457","DOI":"10.3748\/wjg.v21.i43.12457","volume":"21","author":"M Kikuchi","year":"2015","unstructured":"Kikuchi, M. et al. Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects. World J. Gastroenterol. 21, 12457\u201312467 (2015).","journal-title":"World J. Gastroenterol."},{"key":"339_CR261","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.clnu.2018.03.006","volume":"38","author":"MT Lopez-Chillon","year":"2019","unstructured":"Lopez-Chillon, M. T. et al. Effects of long-term consumption of broccoli sprouts on inflammatory markers in overweight subjects. Clin. Nutr. 38, 745\u2013752 (2019).","journal-title":"Clin. Nutr."},{"key":"339_CR262","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.foodchem.2014.10.152","volume":"173","author":"S Medina","year":"2015","unstructured":"Medina, S. et al. The intake of broccoli sprouts modulates the inflammatory and vascular prostanoids but not the oxidative stress-related isoprostanes in healthy humans. Food Chem. 173, 1187\u20131194 (2015).","journal-title":"Food Chem."},{"key":"339_CR263","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4477","volume":"9","author":"AS Axelsson","year":"2017","unstructured":"Axelsson, A. S. et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Sci. Transl Med. 9, eaah4477 (2017).","journal-title":"Sci. Transl Med."},{"key":"339_CR264","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/cvr\/cvx045","volume":"113","author":"LS Mansor","year":"2017","unstructured":"Mansor, L. S. et al. Inhibition of sarcolemmal FAT\/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia\/reoxygenation. Cardiovasc. Res. 113, 737\u2013748 (2017).","journal-title":"Cardiovasc. Res."},{"key":"339_CR265","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1172\/JCI97233","volume":"127","author":"DJ Drucker","year":"2017","unstructured":"Drucker, D. J., Habener, J. F. & Holst, J. J. Discovery, characterization, and clinical development of the glucagon-like peptides. J. Clin. Invest. 127, 4217\u20134227 (2017).","journal-title":"J. Clin. Invest."},{"key":"339_CR266","first-page":"630537","volume":"2013","author":"J Liu","year":"2013","unstructured":"Liu, J., Liu, Y., Chen, L., Wang, Y. & Li, J. Glucagon-Like peptide-1 analog liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J. Diabetes Res. 2013, 630537 (2013).","journal-title":"J. Diabetes Res."},{"key":"339_CR267","volume":"17","author":"L Wu","year":"2018","unstructured":"Wu, L. et al. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPAR\u03b1 pathway. Aging Cell 17, e12763 (2018).","journal-title":"Aging Cell"},{"key":"339_CR268","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvu223","volume":"104","author":"N Hamdani","year":"2014","unstructured":"Hamdani, N. et al. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc. Res. 104, 423\u2013431 (2014).","journal-title":"Cardiovasc. Res."},{"key":"339_CR269","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98, 2088\u20132093 (1998).","journal-title":"Circulation"},{"key":"339_CR270","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/dmrr.410","volume":"19","author":"SK Kim","year":"2003","unstructured":"Kim, S. K. et al. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-\u03b1 or -\u03b3 agonists in a type 2 diabetic animal model. Diabetes Metab. Res. Rev. 19, 487\u2013493 (2003).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"339_CR271","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-8-16","volume":"8","author":"F Forcheron","year":"2009","unstructured":"Forcheron, F. et al. Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model\u2013the Zucker diabetic rat. Cardiovasc. Diabetol. 8, 16 (2009).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR272","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1074248409356557","volume":"15","author":"A Baraka","year":"2010","unstructured":"Baraka, A. & AbdelGawad, H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J. Cardiovasc. Pharmacol. Ther. 15, 175\u2013181 (2010).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"339_CR273","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/CS20150623","volume":"130","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Fenofibrate increases cardiac autophagy via FGF21\/SIRT1 and prevents fibrosis and inflammation in the hearts of type 1 diabetic mice. Clin. Sci. 130, 625\u2013641 (2016).","journal-title":"Clin. Sci."},{"key":"339_CR274","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11886-011-0238-6","volume":"14","author":"T Terry","year":"2012","unstructured":"Terry, T., Raravikar, K., Chokrungvaranon, N. & Reaven, P. D. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr. Cardiol. Rep. 14, 79\u201388 (2012).","journal-title":"Curr. Cardiol. Rep."},{"key":"339_CR275","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20132019. Diabetes Care 42, S90\u2013S102 (2019).","journal-title":"Diabetes Care"},{"key":"339_CR276","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/pedi.12493","volume":"18","author":"RA Al Khalifah","year":"2017","unstructured":"Al Khalifah, R. A., Alnhdi, A., Alghar, H., Alanazi, M. & Florez, I. D. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr. Diabetes 18, 664\u2013673 (2017).","journal-title":"Pediatr. Diabetes"},{"key":"339_CR277","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","volume":"5","author":"JR Petrie","year":"2017","unstructured":"Petrie, J. R. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 5, 597\u2013609 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"339_CR278","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/1060028019859323","volume":"53","author":"K Patel","year":"2019","unstructured":"Patel, K. & Carbone, A. Sodium-glucose cotransporters as potential therapeutic targets in patients with type 1 diabetes mellitus: an update on phase 3 clinical trial data. Ann. Pharmacother. 53, 1227\u20131237 (2019).","journal-title":"Ann. Pharmacother."},{"key":"339_CR279","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne, T. et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42, 1147\u20131154 (2019).","journal-title":"Diabetes Care"},{"key":"339_CR280","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2337\/db12-0546","volume":"62","author":"SM Genuth","year":"2013","unstructured":"Genuth, S. M. et al. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT\/EDIC. Diabetes 62, 3561\u20133569 (2013).","journal-title":"Diabetes"},{"key":"339_CR281","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2337\/dc18-1574","volume":"42","author":"BH Braffett","year":"2019","unstructured":"Braffett, B. H. et al. Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT\/EDIC study. Diabetes Care 42, 657\u2013664 (2019).","journal-title":"Diabetes Care"},{"key":"339_CR282","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2005.10.008","volume":"151","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian, S., Horwich, T. B. & Fonarow, G. C. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am. Heart J. 151, 91 (2006).","journal-title":"Am. Heart J."},{"key":"339_CR283","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1540-8159.2008.01206.x","volume":"31","author":"M Mangiavacchi","year":"2008","unstructured":"Mangiavacchi, M. et al. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. Pacing Clin. Electrophysiol. 31, 1425\u20131432 (2008).","journal-title":"Pacing Clin. Electrophysiol."},{"key":"339_CR284","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ejhf.1146","volume":"20","author":"F Cosmi","year":"2018","unstructured":"Cosmi, F. et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur. J. Heart Fail. 20, 888\u2013895 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR285","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","volume":"57","author":"F Arturi","year":"2017","unstructured":"Arturi, F. et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine 57, 464\u2013473 (2017).","journal-title":"Endocrine"},{"key":"339_CR286","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","volume":"17","author":"V Lambadiari","year":"2018","unstructured":"Lambadiari, V. et al. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc. Diabetol. 17, 8 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR287","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"339_CR288","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","volume":"138","author":"S Verma","year":"2018","unstructured":"Verma, S. et al. Effects of Liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 138, 2884\u20132894 (2018).","journal-title":"Circulation"},{"key":"339_CR289","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies, K. B. et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316, 500\u2013508 (2016).","journal-title":"JAMA"},{"key":"339_CR290","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669\u20132701 (2018).","journal-title":"Diabetes Care"},{"key":"339_CR291","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","volume":"122","author":"M Packer","year":"2018","unstructured":"Packer, M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circ. Res. 122, 928\u2013932 (2018).","journal-title":"Circ. Res."},{"key":"339_CR292","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jjcc.2018.07.004","volume":"73","author":"M Sano","year":"2019","unstructured":"Sano, M. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. J. Cardiol. 73, 28\u201332 (2019).","journal-title":"J. Cardiol."},{"key":"339_CR293","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-0031-1297968","volume":"120","author":"YH Chen","year":"2012","unstructured":"Chen, Y. H., Feng, B. & Chen, Z. W. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp. Clin. Endocrinol. Diabetes 120, 116\u2013120 (2012).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"339_CR294","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone, N. J. et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 63, 2889\u20132934 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR295","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","volume":"15","author":"BB Adhyaru","year":"2018","unstructured":"Adhyaru, B. B. & Jacobson, T. A. Safety and efficacy of statin therapy. Nat. Rev. Cardiol. 15, 757\u2013769 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"339_CR296","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones, D. M. et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 70, 1785\u20131822 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR297","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12872-017-0599-x","volume":"17","author":"CSC Fung","year":"2017","unstructured":"Fung, C. S. C., Wan, E. Y. F., Chan, A. K. C. & Lam, C. L. K. Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. BMC Cardiovasc. Disord. 17, 166 (2017).","journal-title":"BMC Cardiovasc. Disord."},{"key":"339_CR298","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1080\/03007995.2018.1439829","volume":"34","author":"PH Chen","year":"2018","unstructured":"Chen, P. H. et al. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Curr. Med. Res. Opin. 34, 1885\u20131892 (2018).","journal-title":"Curr. Med. Res. Opin."},{"key":"339_CR299","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849\u20131861 (2005).","journal-title":"Lancet"},{"key":"339_CR300","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","volume":"32","author":"R Scott","year":"2009","unstructured":"Scott, R. et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493\u2013498 (2009).","journal-title":"Diabetes Care"},{"key":"339_CR301","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2337\/dc13-2334","volume":"37","author":"KL Margolis","year":"2014","unstructured":"Margolis, K. L. et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care 37, 1721\u20131728 (2014).","journal-title":"Diabetes Care"},{"key":"339_CR302","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamacardio.2016.4828","volume":"2","author":"MB Elam","year":"2017","unstructured":"Elam, M. B. et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2, 370\u2013380 (2017).","journal-title":"JAMA Cardiol."},{"key":"339_CR303","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.amjcard.2019.08.038","volume":"124","author":"RK Ghosh","year":"2019","unstructured":"Ghosh, R. K. et al. Sodium glucose co-transporter 2 inhibitors and heart failure. Am. J. Cardiol. 124, 1790\u20131796 (2019).","journal-title":"Am. J. Cardiol."},{"key":"339_CR304","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1753-0407.12621","volume":"10","author":"P Ranasinghe","year":"2018","unstructured":"Ranasinghe, P. et al. Zinc supplementation in prediabetes: a randomized double-blind placebo-controlled clinical trial. J. Diabetes 10, 386\u2013397 (2018).","journal-title":"J. Diabetes"},{"key":"339_CR305","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jtemb.2019.05.007","volume":"55","author":"S Asghari","year":"2019","unstructured":"Asghari, S., Hosseinzadeh-Attar, M. J., Alipoor, E., Sehat, M. & Mohajeri-Tehrani, M. R. Effects of zinc supplementation on serum adiponectin concentration and glycemic control in patients with type 2 diabetes. J. Trace Elem. Med. Biol. 55, 20\u201325 (2019).","journal-title":"J. Trace Elem. Med. Biol."},{"key":"339_CR306","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jnutbio.2018.02.008","volume":"56","author":"ES Eshak","year":"2018","unstructured":"Eshak, E. S. et al. Associations between copper and zinc intakes from diet and mortality from cardiovascular disease in a large population-based prospective cohort study. J. Nutr. Biochem. 56, 126\u2013132 (2018).","journal-title":"J. Nutr. Biochem."},{"key":"339_CR307","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.diabres.2019.06.012","volume":"154","author":"A Bashir","year":"2019","unstructured":"Bashir, A., Azharuddin, M., Rashid, I., Murti, K. & Pandey, K. Predictors of cardiomyopathy in patients with type-2 diabetes mellitus with and without cardiovascular complications: a cross-sectional study. Diabetes Res. Clin. Pract. 154, 90\u2013100 (2019).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"339_CR308","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.atherosclerosis.2011.07.097","volume":"219","author":"RC Seet","year":"2011","unstructured":"Seet, R. C. et al. Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels. Atherosclerosis 219, 231\u2013239 (2011).","journal-title":"Atherosclerosis"},{"key":"339_CR309","doi-asserted-by":"crossref","first-page":"E707","DOI":"10.3390\/nu8110707","volume":"8","author":"A Chu","year":"2016","unstructured":"Chu, A., Foster, M. & Samman, S. Zinc status and risk of cardiovascular diseases and type 2 diabetes mellitus\u2013a systematic review of prospective cohort studies. Nutrients 8, E707 (2016).","journal-title":"Nutrients"},{"key":"339_CR310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ajcn\/nqz041","volume":"110","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Zinc supplementation improves glycemic control for diabetes prevention and management: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 110, 76\u201390 (2019).","journal-title":"Am. J. Clin. Nutr."},{"key":"339_CR311","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.3390\/nu10010038","volume":"10","author":"AH Milton","year":"2018","unstructured":"Milton, A. H. et al. Prospective study of dietary zinc intake and risk of cardiovascular disease in women. Nutrients 10, E38 (2018).","journal-title":"Nutrients"},{"key":"339_CR312","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12011-018-1611-8","volume":"188","author":"M Ruz","year":"2019","unstructured":"Ruz, M. et al. Nutritional effects of zinc on metabolic syndrome and type 2 diabetes: mechanisms and main findings in human studies. Biol. Trace Elem. Res. 188, 177\u2013188 (2019).","journal-title":"Biol. Trace Elem. Res."},{"key":"339_CR313","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2018.04.082","volume":"268","author":"S Costantino","year":"2018","unstructured":"Costantino, S. et al. Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66(Shc). Int. J. Cardiol. 268, 179\u2013186 (2018).","journal-title":"Int. J. Cardiol."},{"key":"339_CR314","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"C Diabetes","year":"1993","unstructured":"Diabetes, C. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","journal-title":"N. Engl. J. Med."},{"key":"339_CR315","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00125-014-3462-y","volume":"58","author":"MA Reddy","year":"2015","unstructured":"Reddy, M. A., Zhang, E. & Natarajan, R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58, 443\u2013455 (2015).","journal-title":"Diabetologia"},{"key":"339_CR316","doi-asserted-by":"crossref","first-page":"H113","DOI":"10.1152\/ajpheart.00440.2018","volume":"316","author":"Y Kang","year":"2019","unstructured":"Kang, Y., Wang, S., Huang, J., Cai, L. & Keller, B. B. Right ventricular dysfunction and remodeling in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 316, H113\u2013H122 (2019).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"339_CR317","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2337\/dc12-0474","volume":"36","author":"RL Widya","year":"2013","unstructured":"Widya, R. L. et al. Right ventricular involvement in diabetic cardiomyopathy. Diabetes Care 36, 457\u2013462 (2013).","journal-title":"Diabetes Care"},{"key":"339_CR318","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2840-9-25","volume":"9","author":"CE van den Brom","year":"2010","unstructured":"van den Brom, C. E. et al. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovasc. Diabetol. 9, 25 (2010).","journal-title":"Cardiovasc. Diabetol."},{"key":"339_CR319","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ejrad.2015.04.026","volume":"84","author":"YZ Chen","year":"2015","unstructured":"Chen, Y. Z. et al. Left ventricular remodeling and fibrosis: sex differences and relationship with diastolic function in hypertrophic cardiomyopathy. Eur. J. Radiol. 84, 1487\u20131492 (2015).","journal-title":"Eur. J. Radiol."},{"key":"339_CR320","doi-asserted-by":"crossref","first-page":"53714","DOI":"10.18632\/oncotarget.16342","volume":"8","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget 8, 53714\u201353729 (2017).","journal-title":"Oncotarget"},{"key":"339_CR321","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18003-8","volume":"7","author":"K Lum-Naihe","year":"2017","unstructured":"Lum-Naihe, K. et al. Cardiovascular disease progression in female Zucker diabetic fatty rats occurs via unique mechanisms compared to males. Sci. Rep. 7, 17823 (2017).","journal-title":"Sci. Rep."},{"key":"339_CR322","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","volume":"283","author":"T Kramer","year":"2019","unstructured":"Kramer, T. et al. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int. J. Cardiol. 283, 152\u2013158 (2019).","journal-title":"Int. J. Cardiol."},{"key":"339_CR323","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego, C. G. et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J. Am. Coll. Cardiol. 73, 1931\u20131944 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"339_CR324","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","volume":"21","author":"SR Yurista","year":"2019","unstructured":"Yurista, S. R. et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail. 21, 862\u2013873 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"339_CR325","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117\u20132128 (2015).","journal-title":"N. Engl. J. Med."},{"key":"339_CR326","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett, D. et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur. Heart J. 37, 1526\u20131534 (2016).","journal-title":"Eur. Heart J."},{"key":"339_CR327","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","volume":"139","author":"E Patorno","year":"2019","unstructured":"Patorno, E. et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation 139, 2822\u20132830 (2019).","journal-title":"Circulation"},{"key":"339_CR328","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc09-S062","volume":"32","author":"American Diabetes Association","year":"2009","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 32, S62\u2013S67 (2009).","journal-title":"Diabetes Care"},{"key":"339_CR329","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11892-013-0405-9","volume":"13","author":"JM Wenzlau","year":"2013","unstructured":"Wenzlau, J. M. & Hutton, J. C. Novel diabetes autoantibodies and prediction of type 1 diabetes. Curr. Diab. Rep. 13, 608\u2013615 (2013).","journal-title":"Curr. Diab. Rep."},{"key":"339_CR330","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2337\/dc13-2359","volume":"37","author":"JM Sosenko","year":"2014","unstructured":"Sosenko, J. M. et al. Use of the diabetes prevention trial-type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 37, 979\u2013984 (2014).","journal-title":"Diabetes Care"},{"key":"339_CR331","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(08)60765-5","volume":"371","author":"V Harjutsalo","year":"2008","unstructured":"Harjutsalo, V., Sjoberg, L. & Tuomilehto, J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 371, 1777\u20131782 (2008).","journal-title":"Lancet"},{"key":"339_CR332","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/329599a0","volume":"329","author":"JA Todd","year":"1987","unstructured":"Todd, J. A., Bell, J. I. & McDevitt, H. O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329, 599\u2013604 (1987).","journal-title":"Nature"},{"key":"339_CR333","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s001250050514","volume":"39","author":"M Rewers","year":"1996","unstructured":"Rewers, M. et al. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 39, 807\u2013812 (1996).","journal-title":"Diabetologia"},{"key":"339_CR334","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/diabetes.48.3.460","volume":"48","author":"AG Ziegler","year":"1999","unstructured":"Ziegler, A. G., Hummel, M., Schenker, M. & Bonifacio, E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes 48, 460\u2013468 (1999).","journal-title":"Diabetes"},{"key":"339_CR335","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s00125-006-0429-7","volume":"49","author":"AK Berg","year":"2006","unstructured":"Berg, A. K., Korsgren, O. & Frisk, G. Induction of the chemokine interferon-\u03b3-inducible protein-10 in human pancreatic islets during enterovirus infection. Diabetologia 49, 2697\u20132703 (2006).","journal-title":"Diabetologia"},{"key":"339_CR336","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","volume":"27","author":"AB Olokoba","year":"2012","unstructured":"Olokoba, A. B., Obateru, O. A. & Olokoba, L. B. Type 2 diabetes mellitus: a review of current trends. Oman Med. J. 27, 269\u2013273 (2012).","journal-title":"Oman Med. J."},{"key":"339_CR337","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature18642","volume":"536","author":"C Fuchsberger","year":"2016","unstructured":"Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41\u201347 (2016).","journal-title":"Nature"},{"key":"339_CR338","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41588-018-0241-6","volume":"50","author":"A Mahajan","year":"2018","unstructured":"Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat. Genet. 50, 1505\u20131513 (2018).","journal-title":"Nat. Genet."},{"key":"339_CR339","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11892-018-1025-1","volume":"18","author":"JN Todd","year":"2018","unstructured":"Todd, J. N., Srinivasan, S. & Pollin, T. I. Advances in the genetics of youth-onset type 2 diabetes. Curr. Diab Rep. 18, 57 (2018).","journal-title":"Curr. Diab Rep."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41569-020-0339-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-020-0339-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41569-020-0339-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:25:09Z","timestamp":1684607109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-020-0339-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":339,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["339"],"URL":"https:\/\/doi.org\/10.1038\/s41569-020-0339-2","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"16 January 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}